NCT04276376 2025-12-01ARIANESGustave Roussy, Cancer Campus, Grand ParisPhase 2 Terminated130 enrolled
NCT02541604 2020-02-25A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid TumorsHoffmann-La RochePhase 1/2 Terminated87 enrolled 41 charts